CDEK
← All organizations

Paratek Pharmaceuticals Inc

For profitContributed to NMEWebsite ↗

Also known as: Paratek Pharmaceuticals | Paratek Pharmaceuticals Inc | PARATEK PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jul 18, 2007

First marketed drug

Oct 2, 2018

First NDA

Oct 2, 2018

Last known activity

May 9, 2023

Acquired by Novo Nordisk on Sep 18, 2023

Timeline

1990s

  1. Jun 1, 1996

    Transcept Pharmaceuticals— Acquired

  2. Jul 1, 1996

    Paratek Pharmaceuticals Inc— Founded

2010s

  1. Oct 2, 2018

    omadacycline— NDA Organization

  2. Oct 2, 2018

    omadacycline— NDA Secondary Org

2020s

  1. Sep 18, 2023

    Novo Nordisk— Acquired By

  2. Mar 20, 2025

    OptiNose ASOptiNose AS— Acquired

Drugs by trial phase (20 distinct, 47 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 1 (1 own, 2 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (1)

Subsidiaries (2 direct, 3 total across the full acquisition tree)

Recent trials (20)

Details

Founded
Boston, MA, US Jul 1, 1996
First NDA
Oct 2, 2018
Last known activity
May 9, 2023

Designations held

  • Fast track
  • Priority review